- Founded: 2016
- CEO: Elizabeth Sharlow
- Company Size: 3
- Funding Source: Grants (e.g. SBIR, CRCF, CIT)
- Development Stage: Pre-clinical
Spun out of the University of Pittsburgh and University of Virginia, KeViRx, Inc. focuses on the development of novel anticancer small molecules. Current lead candidate, KVR053, is an allosteric PTP4A3 phosphatase small molecule inhibitor that has potent activity in cell-based models of ovarian cancer. KVR053 also displays anti-tumor activity in vivo models of ovarian cancer.